A detailed history of Kbc Group Nv transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 2,997 shares of VKTX stock, worth $157,612. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,997
Previous 2,524 18.74%
Holding current value
$157,612
Previous $134,000 41.79%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$49.84 - $70.47 $23,574 - $33,332
473 Added 18.74%
2,997 $190,000
Q2 2024

Jul 17, 2024

BUY
$47.39 - $80.2 $34,879 - $59,027
736 Added 41.16%
2,524 $134,000
Q1 2024

May 08, 2024

BUY
$17.4 - $94.5 $31,111 - $168,966
1,788 New
1,788 $147,000
Q3 2023

Feb 15, 2024

BUY
$10.92 - $16.0 $15,779 - $23,120
1,445 New
1,445 $16,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.